Last reviewed: June 27, 2026
Last updated: June 27, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Wegovy, the brand-name injectable semaglutide, became FDA-approved in June 2021 specifically for weight loss in adults with a body mass index of 30 or higher, or those with a BMI of 27 or higher plus weight-related health conditions. This approval marked a major shift in how weight management is treated as a chronic medical condition rather than a lifestyle issue alone. PlexusDx offers compounded semaglutide injections from licensed 503A pharmacies as a more accessible alternative, starting at $149 per month.
FDA Approval Timeline for Semaglutide Weight Loss
Semaglutide's journey to weight loss approval began years before Wegovy hit the market. The drug was originally developed and approved by the FDA in 2017 as Ozempic for type 2 diabetes management. Researchers noticed a striking side effect: patients taking semaglutide for blood sugar control experienced significant weight reduction, which led to dedicated clinical trials for weight management.
In 2021, the FDA granted approval to Wegovy (semaglutide 2.4 mg weekly injection) based on the STEP clinical trial program. These landmark studies showed adults using semaglutide lost an average of 15% of their body weight over 68 weeks, compared to 2.4% in the placebo group. This robust evidence demonstrated that semaglutide met FDA safety and efficacy standards specifically for chronic weight management.
How Semaglutide Works for Weight Loss
Semaglutide is a glucagon-like peptide-1 receptor agonist, or GLP-1 RA, that works by mimicking a natural hormone your gut produces when you eat. This hormone signals your brain to reduce hunger, increase feelings of fullness, and regulate blood sugar levels. When you inject semaglutide weekly, it binds to GLP-1 receptors throughout your body and brain, triggering these appetite-suppressing and metabolism-supporting effects.
The medication also slows how quickly your stomach empties after meals, which means food stays in your digestive system longer and you feel satisfied longer. This dual mechanism—reduced hunger signals plus extended satiety—makes it easier to consume fewer calories without the constant struggle many people experience with traditional dieting. PlexusDx's compounded semaglutide injections work through the identical biological pathway as Wegovy, delivering the same active ingredient through licensed 503A pharmacies.
Clinical Evidence and Real-World Weight Loss Results
The STEP trials enrolled over 4,500 adults across multiple studies and followed them for up to 68 weeks on semaglutide therapy. Participants with obesity and no prior diabetes history lost 9.2 to 17.4% of their baseline body weight depending on the dose and study cohort. Beyond weight reduction, patients also experienced improvements in cardiovascular risk factors including blood pressure, cholesterol, and inflammatory markers.
Post-marketing data from real-world use shows that results continue beyond the trial period when patients maintain their injections. Studies tracking semaglutide users over 2+ years demonstrate sustained weight loss and metabolic improvements, particularly when combined with lifestyle modifications. The FDA's approval of semaglutide for chronic weight management recognizes that effective treatment often requires ongoing therapy, similar to how blood pressure or cholesterol medications work long-term.
Affordability and Access: Compounded vs. Brand-Name Options
While Wegovy is FDA-approved, its brand-name price can exceed $900 to $1,300 per month, creating a significant barrier for many people who could benefit. PlexusDx provides compounded semaglutide injections from licensed 503A compounding pharmacies starting at $149 per month, with no insurance requirement and no membership fees. This pricing structure reflects PlexusDx's commitment to making peptide therapy accessible across all 50 states.
PlexusDx also accepts HSA and FSA contributions toward compounded semaglutide, further reducing your out-of-pocket costs. While compounded medications are not FDA-approved (as compounding creates individualized preparations), they are produced under strict quality and safety standards in licensed 503A pharmacies. The active pharmaceutical ingredient in PlexusDx's semaglutide is identical to what the FDA approved in Wegovy, ensuring you receive evidence-based therapy at a fraction of the brand-name cost.
Personalization Through Genetic Testing for Semaglutide Response
Not everyone responds to semaglutide in the same way, and some individuals experience stronger appetite suppression and weight loss than others. PlexusDx offers the Precision Peptide Genetic Test ($99 after your first month of treatment), which analyzes genetic variants in key pathways that influence how your body responds to GLP-1 therapy. The test examines variants like GLP1R rs6923761, which directly affects how your cells respond to the GLP-1 signal that semaglutide creates.
By mapping 14 peptide pathways and 49 individual peptides across 150+ genetic insights, PlexusDx helps identify whether your genetics predict strong response to semaglutide alone or whether a dual-compound approach like GLP-Squared (semaglutide plus tirzepatide) might work better for your body. This personalization reduces trial-and-error medication selection and helps you achieve faster, more sustainable weight loss based on your unique biology.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Wegovy FDA-approved for weight loss?
Yes, Wegovy (semaglutide 2.4 mg) received FDA approval in June 2021 specifically for chronic weight management in adults with obesity or overweight conditions plus weight-related health issues. The approval was based on the STEP clinical trials, which showed average weight loss of 15% over 68 weeks on semaglutide versus 2.4% with placebo.
What's the difference between Ozempic, Wegovy, and compounded semaglutide?
Ozempic is FDA-approved for type 2 diabetes at lower doses (0.5–1 mg weekly), while Wegovy is the same active ingredient approved for weight loss at a higher dose (2.4 mg weekly). PlexusDx's compounded semaglutide is produced in licensed 503A pharmacies and contains the identical semaglutide molecule, but costs $149 per month versus Wegovy's $900+ price tag.
How much weight can I expect to lose with semaglutide?
Clinical trials show average weight loss of 15% of baseline body weight over 68 weeks on semaglutide, though individual results vary from 9% to 17% depending on dose, adherence, and genetics. PlexusDx's Precision Peptide Genetic Test can help predict your likely response by analyzing GLP-1 receptor variants and related metabolic pathways.
Are compounded semaglutide injections as safe as Wegovy?
PlexusDx's compounded semaglutide is produced in licensed 503A pharmacies under strict quality and safety standards, though it is not FDA-approved as a compounded preparation. The active pharmaceutical ingredient is identical to FDA-approved Wegovy, and side effect profiles are equivalent. Common side effects include nausea and gastrointestinal changes, which typically decrease over time.
How does the Precision Peptide Genetic Test help with semaglutide?
The test analyzes genetic variants like GLP1R rs6923761 and others across 14 peptide pathways, revealing whether you're genetically predisposed to strong semaglutide response or whether a dual-compound therapy like GLP-Squared might work better. This personalization helps you start with the therapy most likely to deliver results for your unique biology.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Understanding Zepbound: How Many Units is 2.5 mg of Zepbound?
Is Wegovy a Shot or a Pill? Choosing Your Best Path to Sustainable Weight Loss